Pravastatin sodium是一种HMG-CoA还原酶抑制剂,能抑制甾醇合成,其IC50为5.6 μM。An HMGCR inhibitor which blocks cholesterol synthesis.
Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM. An HMGCR inhibitor which blocks cholesterol synthesis.
1.Ruifeng Liang, Wenjing Ge, Bingjie Li, Weifeng Cui, Xiaofan Ma, Yuying Pan, Gengsheng Li. (2022) Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs. PHARMACEUTICAL BIOLOGY, [PMID:35171063][10.1080/13880209.2022.2036767]
2.Wei Wu, Rui Cheng, Zhenzhou Jiang, Luyong Zhang, Xin Huang. (2021) UPLC–MS/MS method for the simultaneous quantification of pravastatin, fexofenadine, rosuvastatin, and methotrexate in a hepatic uptake model and its application to the possible drug–drug interaction study of triptolide. BIOMEDICAL CHROMATOGRAPHY, 35 (7):(e5093). [PMID:33634891][10.1002/bmc.5093]
3.Binbin Sun, Zeyu Zhong, Fan Wang, Jiong Xu, Feng Xu, Weimin Kong, Zhaoli Ling, Nan Shu, Ying Li, Tong Wu, Mian Zhang, Liang Zhu, Xiaodong Liu, Li Liu. (2018) Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation. BIOCHEMICAL PHARMACOLOGY, [PMID:29338971][10.1016/j.bcp.2018.01.021]